CABA Cabaletta Bio, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.82

Period return

-0.12 (-4.08%)

Volume

2.6M

2026-07-21O $2.74 H $2.86 L $2.73 C $2.82MA5 $2.77MA20 $2.95MA60 $3.24MA120 $3.12

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.LowHOLD2 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.01%
2026. 05. 04.LowBUY3 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 03. 24.LowBUY4 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 03. 24.LowBUY4 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2025. 10. 31.LowBUY9 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2025. 10. 10.LowBUY9 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 09. 05.LowBUY11 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $13.38 · 8 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology

Cabaletta Bio, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 15.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight
2026. 05. 04.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight
2026. 03. 24.	Morgan Stanley	—	Maintain	Overweight → Overweight	—	Morgan Stanley: Overweight
2026. 03. 24.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2025. 10. 31.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight
2025. 10. 10.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,497,917	$6.72M	0.01%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,839,799	$4.03M	0.01%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	246,615	$663.39K	0.00%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	56,648	$124.06K	0.00%	—	New position